{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Class (Stereo):
CHEMICAL (ACHIRAL)
Nifurthiazole, a 5-nitrofuran derivative, is an antibacterial and antiprotozoal agent, it is active against Trypanosoma. It was also used for controlling Salmonella choleraesuis in swine. The mode of action of 5-nitrofuran analogues is based on red-ox biotransformation.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Uredepa, a thiotepa derivative, is a antineoplastic, alkylating agent. It has also been used experimentally as an insect chemosterilant.
Status:
Investigational
Source:
INN:iocanlidic acid (¹²³I) [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Iocanlidic Acid I-123 is a radiolabeled phenylfatty acid derivative studied as a diagnostic agent for myocardial imaging
Class (Stereo):
CHEMICAL (ACHIRAL)
Pelretin is an antikeratinizing agent that was in phase II trials for the treatment of skin disorders. However, these studies were discontinued. In addition, pelretin was studied in cosmetic as a cream to treat acne and against skin wrinkling. Information about the further development of pelretin is not available.
Status:
Investigational
Source:
NCT01239069: Phase 2 Interventional Completed Dry Eye
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tomicorat is an anti-inflammatory agent.
Status:
Investigational
Source:
NCT00741442: Phase 2 Interventional Completed Hyperuricemia
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
USAN:METHYL PALMOXIRATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Methyl palmoxirate, an oral hypoglycemic agent, was studied as a selective and irreversible inhibitor of the mitochondrial enzyme carnitine palmitoyltransferase and of long-chain fatty acid oxidation to treat diabetes. In addition, this compound was used to study the brain lipid metabolism by quantitative autoradiography or positron emission tomography (PET).
Class (Stereo):
CHEMICAL (MIXED)
Enisoprost is a prostaglandin E1 analog. Enisoprost exerts immunosuppressive activity and gastric antisecretory effect. Enisoprost was being studied for the treatment of peptic ulcer and transplant rejection. Enisoprost development has been discontinued.
Class (Stereo):
CHEMICAL (RACEMIC)
Suriclone is a dithiinopyrrole derivative patented by Rhone-Poulenc S. A. as a sedative and anxiolytic drug. The mechanism of action by which suriclone produces it's sedative and anxiolytic effects is by modulating GABAA receptors, although suriclone is more subtype-selective than most benzodiazepines. In clinical trials, Suriclone shows a significant anxiolytic effect. The most common adverse reaction was dizziness.
Status:
Investigational
Source:
NCT01316809: Phase 1 Interventional Completed Glioblastoma Multiforme
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
AstraZeneca was developing AZD-8055, an orally active mTORC1/mTORC2 inhibitor, for the treatment of advanced solid tumours. AZD-8055 is an ATP-competitive mTORC1/2 inhibitor that exhibits immunosuppressive and anticancer chemotherapeutic activities. AZD-8055 promotes antibody class switching in B cells at low doses and decreases B cell proliferation and differentiation at high doses. In vivo, this compound suppresses CC4 and CD8 T cell proliferation, increasing survival among MHC-mismatched heart transplant recipients. In vitro, AZD-8055 decreases viability of brain tumor cells; in vivo, it inhibits tumor growth. AZD-8055 had been in phase I trials by AstraZeneca for the treatment of malignant gliomas and solid tumours. However, this research has been discontinued.
